We are talking about a new direction in medicine and oncology – theranostics, when radiopharmaceuticals (RP) are used not only in diagnosis, but also in the treatment of advanced stages of oncological diseases.
“Now we treat radiopharmaceuticals in patients with hormone-resistant forms of prostate cancer, when other methods have exhausted themselves, and people with advanced stages of neuroendocrine tumors (a disease that can affect the pancreas, gastrointestinal tract, bronchopulmonary system, and other organs)”, he said.
A number of patients in the terminal (last) stage of prostate cancer received the radiopharmaceutical “Actinium – PSMA”.
“The experience of the first applications showed positive results. Patients from a state of terminally ill patients who were shown to stay in a hospice returned to their families and do not experience everyday difficulties, and half even returned to work,” Maistrenko added.
According to him, the results of treatment with another radiopharmaceutical, Actinium-DOTATE, are also impressive. It was received by patients with a neuroendocrine tumor at the stage of uncontrolled spread of the process, when they had multiple metastases. After three courses of treatment, there were no living metastases (those that can lead to disease progression) in the examination of living metastases in these patients.
Read more in the exclusive Izvestia article:
“Patients who were shown to stay in a hospice returned to their families”